Knights of Columbus Asset Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22,533	Closed	-$1.65M	–	423
2024 Q3	$1.65M	Sell	22,533 -21,848	-49%	-$1.64M	0.11%	203
2024 Q2	$3.04M	Buy	44,381 +7,517	+20%	+$521K	0.2%	170
2024 Q1	$2.55M	Sell	36,864 -17,635	-32%	-$1.21M	0.18%	176
2023 Q4	$3.9M	Buy	54,499 +27,331	+101%	+$1.57M	0.25%	175
2023 Q3	$1.42M	Buy	27,168 +3,464	+15%	+$202K	0.13%	223
2023 Q2	$1.5M	Buy	23,704 +52	+0.2%	+$3.24K	0.13%	218
2023 Q1	$1.28M	Buy	23,652 +146	+0.6%	+$7.06K	0.13%	224
2022 Q4	$1.24M	Buy	23,506 +12,016	+105%	+$602K	0.13%	218
2022 Q3	$535K	Buy	11,490 +1,367	+14%	+$71.4K	0.05%	240
2022 Q2	$578K	Buy	+10,123	New	+$574K	0.06%	244

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Knights of Columbus Asset Advisors's ITCI Position: Q4 2024 in Review

Knights of Columbus Asset Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 22,533 shares — an estimated $1.65M sold.

Knights of Columbus Asset Advisors first reported a position in ITCI in Q2 2022 and held it in 10 quarters. The position peaked at $3.9M in Q4 2023. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

Knights of Columbus Asset Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 22,533 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $1.65M.
Knights of Columbus Asset Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 10 quarters.
Knights of Columbus Asset Advisors's Intra-Cellular Therapies Inc. position peaked at $3.9M in Q4 2023.
387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on Knights of Columbus Asset Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.